CHMP backs world’s first Ebola vaccine from MSD, NewLinkMerck & Co/MSD’s Ebola vaccine has been recommended for conditional approval by the EMA’s main advisory committee, teeing Share XCHMP backs world’s first Ebola vaccine from MSD, NewLinkhttps://pharmaphorum.com/news/chmp-backs-worlds-first-ebola-vaccine-from-msd-newlink/
Pharma must rebuild reputation – Merck and Co’s CEOMerck & Co’s CEO Kenneth Frazier has said the pharma industry must take on the challenge of its Share XPharma must rebuild reputation – Merck and Co’s CEOhttps://pharmaphorum.com/news/pharma-must-rebuild-reputation-merck-cos-ceo/
Merck and Co’s cancer drug Keytruda to smash sales records by 2023 – forecastMerck & Co’s Keytruda cancer immunotherapy is set to become the world’s top-selling drug by annual revenue in Share XMerck and Co’s cancer drug Keytruda to smash sales records by 2023 – forecasthttps://pharmaphorum.com/news/mercks-cancer-drug-keytruda-to-smash-sales-records-by-2023-forecast/
ESMO 2019 roundupThe European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma Share XESMO 2019 rounduphttps://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/
Merck & Co hopes for foothold in early TNBC after Keytruda trial winMerck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold Share XMerck & Co hopes for foothold in early TNBC after Keytruda trial winhttps://pharmaphorum.com/news/merck-co-hopes-for-foothold-in-early-tnbc/
Merck, Eisai get triple approvals for Keytruda/Lenvima combinationThe combination of Merck & Co’s Keytruda with targeted drug Lenvima has been approved for endometrial cancer in Share XMerck, Eisai get triple approvals for Keytruda/Lenvima combinationhttps://pharmaphorum.com/news/merck-eisai-get-triple-approvals-for-keytruda-lenvima-combination/
Merck & Co in pole position for Ebola vaccine approval as FDA begins reviewThe FDA is to review Merck & Co’s Ebola vaccine, giving the US pharma a chance to grab Share XMerck & Co in pole position for Ebola vaccine approval as FDA begins reviewhttps://pharmaphorum.com/news/fda-to-review-merck-cos-ebola-vaccine/
BMS’ Opdivo misses target in aggressive brain cancer trialIt’s never good news when a drug firm posts an “update” about a phase 3 trial, and Bristol-Myers Share XBMS’ Opdivo misses target in aggressive brain cancer trialhttps://pharmaphorum.com/news/bms-opdivo-off-target-in-aggressive-brain-cancer/
Keytruda combo cleared as first-line kidney cancer treatment in EUMerck & Co/MSD’s Keytruda has added first-line kidney cancer treatment to its ever-lengthening list of approved uses in Share XKeytruda combo cleared as first-line kidney cancer treatment in EUhttps://pharmaphorum.com/news/keytruda-combo-cleared-first-line-kidney-cancer-treatment-eu/
